ReDS (878324)

  https://cordis.europa.eu/project/id/878324

  Horizon 2020 (2014-2020)

  A disruptive, life-saving solution for home monitoring and management of lung fluid congestion in heart failure patients

  SME instrument (EIC-SMEInst-2018-2020)

  artificial intelligence  ·  mortality  ·  pharmaceutical drugs  ·  radar  ·  cardiology

  2019-09-01 Start Date (YY-MM-DD)

  2019-12-31 End Date (YY-MM-DD)

  € 71,429 Total Cost

  Description

Heart failure (HF) is one of the main causes of mortality and hospitalization worldwide, affecting around 26M people globally, and the most common cause of hospitalization for people over 65. Lung fluid congestion is one of the main HF-related clinical conditions, which leads to a vicious cycle of repeated hospitalizations of HF patients. Strikingly, 1 in 4 patients are readmitted to the hospital within 30 days, and 1 in 2 patients within 6 months. The key challenge is to enable early detection, continuous monitoring and timely treatment of symptoms before the patient undergoes respiratory distress. In fact, current lung fluid monitoring practices are mostly inaccurate and inefficient, enabling detection only at very advanced stages, when symptoms cannot be prevented by simply changing the medication. Sensible introduces ReDS™, a non-invasive home monitoring system for lung fluid congestion in HF patients. The monitoring procedure can be performed by the patient at home in just 90 seconds. The results are processed by an Artificial Intelligence (AI)-driven patient management platform and sent automatically to the physician. The unique proprietary AI algorithm supports physicians in identifying the best treatment based on each patients’ needs and general health status. ReDS™ is the first solution that enables accurate, remote monitoring and management of fluid congestion in HF patients after discharge. During the phase 1 feasibility study, Sensible will define a minimum viable product, establish a sound go-to-market strategy and supply chain, and draft further development plans. During the second phase of the innovation project, Sensible will optimize the device engineering for home use, optimize the AI algorithm, scale-up device manufacturing and perform clinical validation with partner hospitals.

  Complicit Organisations

1 Israeli organisation participates in ReDS.